Beta-Blocker and Calcium-Channel-Blocker Overdose: Glucagon, Insulin and Beyond
Two of the most common cardiac prescriptions sit in almost every medicine cabinet — and taken in overdose they kill the same way: a heart too slow and too weak to keep blood moving. Beta-blockers and calcium-channel blockers arrive by different doors but end up in the same room, choking off the signal that tells the myocardium to beat harder. What makes them a rite of passage in toxicology is not the poisoning but the antidote — a strange, escalating toolkit where you reach past adrenaline for glucagon, then flood a failing heart with insulin, and, when all else fails, take over the circulation with a machine. This is where knowing the mechanism, not the monograph, saves the patient.
A 58-year-old man is brought in an hour after swallowing his wife's diltiazem — a bottle nearly full. He is awake but grey, clammy and slow to answer. The monitor shows a heart rate of 38 and a blood pressure of 70 over 40. Atropine is given and barely nudges the rate. A bedside glucose comes back high — 14 mmol/L — in a man who is not diabetic, and the toxicologist on the phone seizes on that number as a clue rather than a distraction. Litres of fluid do little. The team does not reach for more adrenaline; they reach for calcium, then glucagon, then set up an insulin infusion running at doses that would terrify anyone who has only ever used insulin to lower sugar. By the time the drip is titrated, his pressure is climbing. He has bought the hours his liver needs to clear the drug.
Two drugs, one final common pathway
Both poisons end at the same place: a heart that cannot raise its own cAMP or move enough calcium. In a healthy heart, sympathetic tone drives the beta-1 receptor, which raises the second messenger cAMP, which opens L-type calcium channels and floods the cell with calcium for each contraction. More calcium in means a faster rate at the SA node, faster conduction through the AV node, and a stronger squeeze. Beta-blockers and calcium-channel blockers attack this axis from opposite ends. A beta-blocker sits on the beta-1 receptor and blunts cAMP production at the source. A calcium-channel blocker leaves the receptor untouched but slams the door the signal was trying to open — the L-type channel itself. Either way the result is the toxidrome of cardiogenic shock: bradycardia, hypotension, and a myocardium too feeble to compensate. This is the same cAMP-and-calcium machinery laid out in the Cardiovascular chapter on the SA/AV node — poisoned in overdose.
Beta-blockers: not all the same poison
The core beta-blocker overdose is bradycardia and hypotension from lost beta-1 drive. But two extra features flag the class. First, hypoglycaemia — beta-blockade impairs the adrenaline-driven glycogenolysis that normally rescues a falling glucose, so a poisoned patient (especially a child) can crash their sugar, and worse, the tachycardia that would warn of it is masked. Second, bronchospasm in anyone with reactive airways, from beta-2 blockade. Then the individual agents diverge in dangerous ways. Propranolol is the villain: it is highly lipophilic, so it crosses into the brain to cause CNS depression and seizures, and it blocks fast sodium channels like a class-I antiarrhythmic — producing a widened QRS and the same membrane-stabilising cardiotoxicity you meet in the TCA and local-anaesthetic (LAST) chapters. Sotalol is the other outlier: it blocks potassium channels, prolonging the QT interval and threatening torsades de pointes. Knowing which beta-blocker you are fighting changes what you watch for.
Calcium-channel blockers: two families, two pictures
Where the drug prefers to act — vessel or node — predicts how the patient looks. Calcium-channel blockers split into two clinically opposite groups. The dihydropyridines — amlodipine, nifedipine — are vasoselective: they relax arterial smooth muscle. In overdose the picture is distributive-looking vasodilatory shock with, at least early on, a reflex tachycardia as the heart tries to compensate. The non-dihydropyridines — verapamil and diltiazem — act on the heart itself, at the SA and AV nodes and the myocardium. These are the true killers of the class: profound bradycardia, AV block, and pump failure, with none of the reflex tachycardia to soften the blow. And in massive overdose the neat selectivity dissolves — amlodipine can become cardiotoxic too. One laboratory clue ties the class together and is worth its weight in gold: calcium-channel blockers cause HYPERglycaemia. The same L-type channels that admit calcium into pancreatic beta cells to trigger insulin release are blocked, so insulin secretion falls and glucose rises. A high sugar in a shocked, bradycardic patient is a fingerprint of CCB poisoning — and, as the antidote section shows, it is also the physiological rationale for treating them with insulin.
Think of the myocardium as a factory floor whose machines only run when a foreman (adrenaline) shouts the order through an intercom (the beta receptor), and the order opens a supply gate (the calcium channel) to deliver raw material (calcium). A beta-blocker gags the intercom — the order never gets loud enough. A calcium-channel blocker leaves the intercom working but chains the supply gate shut. Glucagon is a clever back-door telephone straight to the machines that bypasses the gagged intercom entirely. And high-dose insulin is like handing the exhausted, starving factory a fresh fuel supply it can actually burn — because a heart in shock abandons its usual diet of fatty acids and runs on sugar instead.
Let the glucose point you to the poison. A bradycardic, hypotensive patient with a HIGH blood sugar and no diabetes is a calcium-channel blocker until proven otherwise — the blocked pancreatic L-type channel has switched off insulin release. Flip it around and the same logic warns you about beta-blockers, where blunted glycogenolysis can drive the sugar LOW, especially in children, with the tell-tale tachycardia masked. One bedside glucose reading quietly separates the two overlapping poisonings and, in the CCB case, points straight at the treatment.
- Both classes converge on collapsed cardiac cAMP/calcium signalling → bradycardia, hypotension, cardiogenic shock.
- Beta-blockers block beta-1 (less cAMP); CCBs block the L-type calcium channel the cAMP signal was opening.
- Beta-blocker extras: hypoglycaemia and bronchospasm; propranolol adds CNS/seizures + wide-QRS (sodium block); sotalol prolongs QT (torsades).
- Dihydropyridines (amlodipine) = vasodilatory shock + reflex tachycardia; non-DHPs (verapamil, diltiazem) = brady + pump failure.
- CCBs classically cause HYPERglycaemia (blocked pancreatic insulin release) — a diagnostic clue and the rationale for HIET.
- Atropine and fluids are first reflexes but are frequently inadequate — plan the antidote ladder early.
The antidote ladder, step one: calcium and glucagon
The early rungs try to force the blocked pathway open again — from both ends. Intravenous calcium is the intuitive first antidote for CCB poisoning: raise the extracellular calcium high enough and some current sneaks through even partially blocked channels, improving contractility and blood pressure. It is given as a bolus and often repeated, and it helps beta-blocker toxicity too, though usually less dramatically — the response is real but frequently incomplete in severe cases, which is the point students miss. Glucagon is the classic beta-blocker antidote and the more elegant idea. It binds its own receptor on the myocyte and activates cardiac adenylyl cyclase directly — raising cAMP without ever touching the beta receptor. It picks up the phone the beta-blocker has cut, restoring rate and contractility by the back door. Glucagon is given as a bolus followed by an infusion; its main nuisance is vomiting (protect the airway) and it depletes stocks fast, since a serious overdose can exhaust a hospital's entire supply. It helps CCB toxicity as well, because raising cAMP is useful whichever end of the pathway is blocked.
Step two: high-dose insulin euglycaemic therapy (HIET)
High-dose insulin euglycaemic therapy is the cornerstone that surprises everyone — it treats the failing heart with a hormone we normally think of as sugar-lowering. There are two reasons it works. First, metabolic: a stressed, poisoned myocardium abandons its preferred fatty-acid fuel and switches to burning carbohydrate, and insulin is what drives glucose into the cell so it can be used — it feeds a starving pump. Second, insulin is itself a positive inotrope, independent of that, strengthening contraction. The doses are an order of magnitude above what treats diabetes — this is insulin as a cardiac drug, not a glucose drug — and it is run with a glucose infusion to keep the sugar normal ("euglycaemic") and with close monitoring of potassium, which insulin drives into cells. It is slow to take effect, so it is started early rather than as a last resort, and it has become a cornerstone for both beta-blocker and calcium-channel-blocker shock. The endocrine logic here — insulin, cellular glucose uptake, and the CCB-induced hyperglycaemia that hints the heart will respond — is the Endocrine chapter's physiology turned into an antidote.
IV calcium — overcomes CCB channel blockade by raising extracellular calcium (helps beta-blockers less). Glucagon — activates cardiac adenylyl cyclase, bypassing the beta receptor to raise cAMP (the classic beta-blocker antidote). High-dose insulin (HIET) — feeds the carbohydrate-hungry myocardium and acts as an inotrope (cornerstone for both). Vasopressors — noradrenaline / adrenaline for refractory hypotension. IV lipid emulsion — a "lipid sink" for very lipophilic drugs (propranolol, verapamil) in periarrest. Atropine and cardiac pacing — tried for bradycardia but frequently ineffective in serious poisoning. ECMO / mechanical circulatory support — the rescue that buys time when the drug simply has to be cleared.
Step three: pressors, lipid, and the machine
When calcium, glucagon and insulin are not enough, vasopressors — noradrenaline or adrenaline — are titrated to hold up the blood pressure, accepting that a beta-blocked heart may respond poorly to adrenergic drugs. For the most lipophilic agents, intravenous lipid emulsion becomes an option in the crashing or peri-arrest patient: the infused fat is thought to act as a "lipid sink," pulling drug like propranolol or verapamil out of the tissues into a circulating lipid compartment — the same rescue used for local-anaesthetic systemic toxicity (LAST) in that chapter. It is a salvage measure, not a first move. And when pharmacology is losing the race against a massive ingestion, the definitive rescue is mechanical: veno-arterial ECMO or another circulatory-support device takes over the work of the heart entirely, keeping the brain and organs perfused while the liver slowly metabolises the drug. The insight that unifies the whole ladder — glucagon and lipid emulsion in particular sit alongside the other reversal agents of the Enhanced-elimination and Antidotes chapter — is that in these two poisonings you are almost never neutralising the toxin; you are supporting the pump until time clears it.
Atropine is a reflex, not a plan. It is reasonable to try once for symptomatic bradycardia, but in serious beta-blocker or calcium-channel-blocker poisoning it — and even transvenous pacing — usually fails, because the problem is not excess vagal tone but a myocardium whose contractile machinery has been switched off. Chasing the heart rate while the blood pressure and perfusion collapse wastes the golden early window. The rate is a distraction; support contractility and output — with calcium, glucagon, and especially early high-dose insulin — and get help from toxicology and ECMO teams before the arrest, not after.
- IV calcium first for CCB shock; raising extracellular calcium forces current through partially blocked channels (weaker effect in beta-blocker toxicity).
- Glucagon = the beta-blocker antidote: it raises cAMP via cardiac adenylyl cyclase, bypassing the blocked beta receptor.
- HIET is a cornerstone for both — start it early; it feeds the sugar-burning myocardium and is a positive inotrope, run euglycaemic with K+ watched.
- Vasopressors for refractory hypotension; IV lipid emulsion as salvage for lipophilic agents (propranolol, verapamil).
- Atropine and pacing are usually ineffective — don't let the heart rate distract from perfusion.
- ECMO is the definitive rescue in massive overdose — support the circulation until the drug is metabolised.
- Chasing the heart rate with repeated atropine (and expecting pacing to work) instead of supporting contractility and output with calcium, glucagon and early HIET.
- Withholding high-dose insulin because the doses "look wrong" or fearing hypoglycaemia — HIET is run euglycaemic with a glucose infusion and is a cornerstone, not a curiosity.
- Forgetting the agent-specific traps: propranolol's wide-QRS (needs sodium bicarbonate, like a TCA) and sotalol's QT prolongation and torsades.
A non-diabetic man presents two hours after a verapamil overdose with a heart rate of 40, blood pressure 72/44, and a bedside glucose of 13 mmol/L. Atropine and a fluid bolus have not helped. Beyond IV calcium, which intervention best targets the underlying cardiotoxicity?
- Beta-blockers (block beta-1 → less cAMP) and CCBs (block the L-type calcium channel) converge on bradycardia, hypotension and cardiogenic shock.
- Class clues: beta-blockers → hypoglycaemia/bronchospasm (propranolol adds seizures + wide QRS; sotalol prolongs QT); CCBs → HYPERglycaemia and, for verapamil/diltiazem, profound brady + pump failure.
- Antidote ladder: IV calcium, glucagon (raises cAMP past the beta receptor), high-dose insulin euglycaemic therapy (a cornerstone for both), vasopressors, lipid emulsion for lipophilic drugs.
- Atropine and pacing usually fail; ECMO is the rescue that supports the circulation until the drug clears — you support the pump, you rarely neutralise the toxin.
- Goldfrank's Toxicologic Emergencies — Beta-adrenergic antagonists; Calcium channel blockers.
- Katzung Basic & Clinical Pharmacology — Beta-receptor & calcium-channel blocking agents; management of overdose.
- Rang & Dale's Pharmacology — Adrenoceptor antagonists and calcium antagonists.
- St-Onge M, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. Critical Care Medicine.
- Engebretsen KM, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clinical Toxicology.
- American College of Medical Toxicology position statement on the use of intravenous lipid emulsion therapy; UpToDate/TOXBASE poisoning topics.
